Glenn Lesser to Antineoplastic Agents
This is a "connection" page, showing publications Glenn Lesser has written about Antineoplastic Agents.
Connection Strength
2.197
-
Lesser GJ, Case D, Stark N, Williford S, Giguere J, Garino LA, Naughton MJ, Vitolins MZ, Lively MO, Shaw EG. A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. J Support Oncol. 2013 Mar; 11(1):31-42.
Score: 0.298
-
Ruiz J, Case D, Enevold G, Rosdhal R, Tatter SB, Ellis TL, McQuellon RP, McMullen KP, Stieber VW, Shaw EG, Lesser GJ. A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. J Neurooncol. 2012 Feb; 106(3):611-7.
Score: 0.268
-
Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011 Mar 08; 76(10):929-30.
Score: 0.259
-
Hong JH, Omur-Ozbek P, Stanek BT, Dietrich AM, Duncan SE, Lee YW, Lesser G. Taste and odor abnormalities in cancer patients. J Support Oncol. 2009 Mar-Apr; 7(2):58-65.
Score: 0.225
-
Renfrow JJ, Soike MH, West JL, Ramkissoon SH, Metheny-Barlow L, Mott RT, Kittel CA, D'Agostino RB, Tatter SB, Laxton AW, Frenkel MB, Hawkins GA, Herpai D, Sanders S, Sarkaria JN, Lesser GJ, Debinski W, Strowd RE. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. Sci Rep. 2020 09 16; 10(1):15195.
Score: 0.125
-
Lycan TW, Hsu FC, Ahn CS, Thomas A, Walker FO, Sangueza OP, Shiozawa Y, Park SH, Peters CM, Romero-Sandoval EA, Melin SA, Sorscher S, Ansley K, Lesser GJ, Cartwright MS, Strowd RE. Neuromuscular ultrasound for taxane peripheral neuropathy in breast cancer. Muscle Nerve. 2020 05; 61(5):587-594.
Score: 0.121
-
Wang A, Duncan SE, Lesser GJ, Ray WK, Dietrich AM. Effect of lactoferrin on taste and smell abnormalities induced by chemotherapy: a proteome analysis. Food Funct. 2018 Sep 19; 9(9):4948-4958.
Score: 0.109
-
Batchelor TT, Gerstner ER, Ye X, Desideri S, Duda DG, Peereboom D, Lesser GJ, Chowdhary S, Wen PY, Grossman S, Supko JG. Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-ß tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neuro Oncol. 2017 04 01; 19(4):567-575.
Score: 0.099
-
Meléndez GC, Sukpraphrute B, D'Agostino RB, Jordan JH, Klepin HD, Ellis L, Lamar Z, Vasu S, Lesser G, Burke GL, Weaver KE, Ntim WO, Hundley WG. Frequency of Left Ventricular End-Diastolic Volume-Mediated Declines in Ejection Fraction in Patients Receiving Potentially Cardiotoxic Cancer Treatment. Am J Cardiol. 2017 05 15; 119(10):1637-1642.
Score: 0.099
-
Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Doherty LM, LaFrankie DC, Pulverenti JR, Rifenburg JA, Ruland SF, Smith KH, Gaffey SC, McCluskey C, Ligon KL, Reardon DA, Wen PY. Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J Neurooncol. 2015 Jan; 121(2):297-302.
Score: 0.083
-
Renfrow JJ, Lesser GJ. Molecular subtyping of brain metastases and implications for therapy. Curr Treat Options Oncol. 2013 Dec; 14(4):514-27.
Score: 0.078
-
Peereboom DM, Supko JG, Carson KA, Batchelor T, Phuphanich S, Lesser G, Mikkelsen T, Mikkelson T, Fisher J, Desideri S, He X, Grossman SA. A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas. J Neurooncol. 2010 Nov; 100(2):261-8.
Score: 0.061
-
Phuphanich S, Supko JG, Carson KA, Grossman SA, Burt Nabors L, Mikkelsen T, Lesser G, Rosenfeld S, Desideri S, Olson JJ. Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol. 2010 Oct; 100(1):95-103.
Score: 0.060
-
Lustig R, Mikkelsen T, Lesser G, Grossman S, Ye X, Desideri S, Fisher J, Wright J. Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. Neuro Oncol. 2008 Dec; 10(6):1004-9.
Score: 0.054
-
Grossman SA, Carson KA, Phuphanich S, Batchelor T, Peereboom D, Nabors LB, Lesser G, Hausheer F, Supko JG. Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. Neuro Oncol. 2008 Aug; 10(4):608-16.
Score: 0.054
-
Phuphanich S, Carson KA, Grossman SA, Lesser G, Olson J, Mikkelsen T, Desideri S, Fisher JD. Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro Oncol. 2008 Aug; 10(4):617-23.
Score: 0.053
-
Grossman SA, Olson J, Batchelor T, Peereboom D, Lesser G, Desideri S, Ye X, Hammour T, Supko JG. Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. Neuro Oncol. 2008 Apr; 10(2):190-8.
Score: 0.052
-
Miller AA, Case D, Harmon M, Savage P, Lesser G, Hurd D, Melin SA. Phase I study of lenalidomide in solid tumors. J Thorac Oncol. 2007 May; 2(5):445-9.
Score: 0.050
-
Grossman SA, Carson KA, Batchelor TT, Lesser G, Mikkelsen T, Alavi JB, Phuphanich S, Hammour T, Fisher JD, Supko JG. The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. Clin Cancer Res. 2006 Sep 01; 12(17):5174-81.
Score: 0.047